peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Financial documents

Financial reports

2023Press releaseReportPresentationWebcastTranscriptXBRL

02 Feb 2024

Year-End Report January-December 2023

26 Oct 2023

Interim report January-September 2023

20 Jul 2023

Interim report January-June 2023

20 Apr 2023

Interim report January-March 2023

Coffee and notepad


Sign up to receive updates on the latest company news and filings

Choose type

I consent to Hansa Biopharma handling my personal data. See our Privacy Policy for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.
Investor Relations

Klaus Sindahl

Head of Investor Relations

Mobile: +46 (0) 709 298 269